PT2812341T - Inibidores c-terminal de hsp90 - Google Patents
Inibidores c-terminal de hsp90Info
- Publication number
- PT2812341T PT2812341T PT137068227T PT13706822T PT2812341T PT 2812341 T PT2812341 T PT 2812341T PT 137068227 T PT137068227 T PT 137068227T PT 13706822 T PT13706822 T PT 13706822T PT 2812341 T PT2812341 T PT 2812341T
- Authority
- PT
- Portugal
- Prior art keywords
- hsp90
- terminal inhibitors
- inhibitors
- terminal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597004P | 2012-02-09 | 2012-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2812341T true PT2812341T (pt) | 2019-11-22 |
Family
ID=47754998
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137068227T PT2812341T (pt) | 2012-02-09 | 2013-02-08 | Inibidores c-terminal de hsp90 |
| PT191935766T PT3656758T (pt) | 2012-02-09 | 2013-02-08 | Intermediários para a preparação de inibidores do cterminal de hsp90 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT191935766T PT3656758T (pt) | 2012-02-09 | 2013-02-08 | Intermediários para a preparação de inibidores do cterminal de hsp90 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US9422320B2 (enExample) |
| EP (3) | EP2812341B1 (enExample) |
| JP (1) | JP6121450B2 (enExample) |
| KR (1) | KR102124109B1 (enExample) |
| CN (2) | CN107474085B (enExample) |
| AU (1) | AU2013216858C1 (enExample) |
| BR (1) | BR112014019704B1 (enExample) |
| CA (1) | CA2866814C (enExample) |
| CY (1) | CY1122358T1 (enExample) |
| DK (2) | DK3656758T3 (enExample) |
| EA (1) | EA027147B1 (enExample) |
| ES (2) | ES2755093T3 (enExample) |
| FI (1) | FI3656758T3 (enExample) |
| HR (2) | HRP20240514T1 (enExample) |
| HU (2) | HUE066259T2 (enExample) |
| LT (2) | LT2812341T (enExample) |
| MX (1) | MX361233B (enExample) |
| NZ (1) | NZ629778A (enExample) |
| PL (2) | PL3656758T3 (enExample) |
| PT (2) | PT2812341T (enExample) |
| RS (2) | RS59719B1 (enExample) |
| SI (2) | SI2812341T1 (enExample) |
| SM (2) | SMT201900660T1 (enExample) |
| WO (1) | WO2013119985A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014019704B1 (pt) | 2012-02-09 | 2022-05-31 | University Of Kansas | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo |
| EP3154964B1 (en) | 2014-06-13 | 2023-04-05 | The University of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| CA3289739A1 (en) * | 2014-06-24 | 2025-11-29 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| WO2016145219A1 (en) * | 2015-03-10 | 2016-09-15 | University Of Florida Research Foundation, Inc. | Treatment of peripheral neuropathies |
| US20210036245A1 (en) * | 2017-12-20 | 2021-02-04 | Merck Patent Gmbh | Heteroaromatic compounds |
| BR112020016205A2 (pt) * | 2018-02-07 | 2020-12-15 | Reata Pharmaceuticals, Inc. | Formas cocristalinas de prolina e de análogo de novobiocina |
| MX2025007723A (es) * | 2018-05-14 | 2025-08-01 | Reata Pharmaceuticals Inc | Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| AU2005301957B2 (en) | 2004-11-03 | 2012-02-23 | Department Of Health And Human Services | Novobiocin analogues as anticancer agents |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| US8846742B2 (en) * | 2006-02-14 | 2014-09-30 | The Trustees Of Columbia University In The City Of New York | Neuronal pain pathway modulators |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP2131656A4 (en) | 2006-11-15 | 2011-12-07 | Forest Lab Holdings Ltd | phthalazine |
| EA019103B1 (ru) | 2007-03-20 | 2014-01-30 | Кьюрис, Инк. | Конденсированный аминопиридин в качестве ингибиторов hsp90 |
| US7960353B2 (en) * | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| JP5766617B2 (ja) | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | 修飾された糖部分を有するノボビオシン類似体 |
| US20110082098A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| TW201216957A (en) | 2010-07-13 | 2012-05-01 | Dainippon Sumitomo Pharma Co | Biarylamide derivative or a pharmaceutically acceptable salt thereof |
| CN101967125B (zh) * | 2010-10-08 | 2012-07-04 | 广州暨南生物医药研究开发基地有限公司 | 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用 |
| MX354215B (es) | 2011-04-05 | 2018-02-19 | Sloan Kettering Inst Cancer Res | Inhibidores de la proteina 90 de choque termico (hsp90). |
| US9056104B2 (en) | 2011-05-20 | 2015-06-16 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
| BR112014019704B1 (pt) | 2012-02-09 | 2022-05-31 | University Of Kansas | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo |
| EP3066072B1 (en) | 2013-11-07 | 2021-11-03 | The University of Kansas | Biphenylamide derivative hsp90 inhibitors |
| WO2015070238A2 (en) | 2013-11-11 | 2015-05-14 | The University Of Kansas | Coumarin based hsp90 inhibitors with urea and ether substituents |
| EP3154964B1 (en) | 2014-06-13 | 2023-04-05 | The University of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| CA3289739A1 (en) | 2014-06-24 | 2025-11-29 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| MX2025007723A (es) | 2018-05-14 | 2025-08-01 | Reata Pharmaceuticals Inc | Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor |
-
2013
- 2013-02-08 BR BR112014019704-0A patent/BR112014019704B1/pt active IP Right Grant
- 2013-02-08 JP JP2014556739A patent/JP6121450B2/ja active Active
- 2013-02-08 SI SI201331622T patent/SI2812341T1/sl unknown
- 2013-02-08 EP EP13706822.7A patent/EP2812341B1/en active Active
- 2013-02-08 AU AU2013216858A patent/AU2013216858C1/en active Active
- 2013-02-08 SM SM20190660T patent/SMT201900660T1/it unknown
- 2013-02-08 DK DK19193576.6T patent/DK3656758T3/da active
- 2013-02-08 CN CN201710729038.6A patent/CN107474085B/zh active Active
- 2013-02-08 HR HRP20240514TT patent/HRP20240514T1/hr unknown
- 2013-02-08 PT PT137068227T patent/PT2812341T/pt unknown
- 2013-02-08 ES ES13706822T patent/ES2755093T3/es active Active
- 2013-02-08 KR KR1020147025348A patent/KR102124109B1/ko active Active
- 2013-02-08 SI SI201332079T patent/SI3656758T1/sl unknown
- 2013-02-08 HU HUE19193576A patent/HUE066259T2/hu unknown
- 2013-02-08 SM SM20240145T patent/SMT202400145T1/it unknown
- 2013-02-08 HU HUE13706822A patent/HUE046939T2/hu unknown
- 2013-02-08 LT LT13706822T patent/LT2812341T/lt unknown
- 2013-02-08 PL PL19193576.6T patent/PL3656758T3/pl unknown
- 2013-02-08 HR HRP20191940TT patent/HRP20191940T1/hr unknown
- 2013-02-08 NZ NZ629778A patent/NZ629778A/en unknown
- 2013-02-08 RS RS20191454A patent/RS59719B1/sr unknown
- 2013-02-08 ES ES19193576T patent/ES2974721T3/es active Active
- 2013-02-08 DK DK13706822T patent/DK2812341T3/da active
- 2013-02-08 FI FIEP19193576.6T patent/FI3656758T3/fi active
- 2013-02-08 US US14/377,616 patent/US9422320B2/en active Active
- 2013-02-08 PL PL13706822T patent/PL2812341T3/pl unknown
- 2013-02-08 RS RS20240452A patent/RS65412B1/sr unknown
- 2013-02-08 EA EA201491496A patent/EA027147B1/ru unknown
- 2013-02-08 PT PT191935766T patent/PT3656758T/pt unknown
- 2013-02-08 MX MX2014009608A patent/MX361233B/es active IP Right Grant
- 2013-02-08 EP EP19193576.6A patent/EP3656758B1/en active Active
- 2013-02-08 CA CA2866814A patent/CA2866814C/en active Active
- 2013-02-08 CN CN201380019057.XA patent/CN104271587B/zh active Active
- 2013-02-08 LT LTEP19193576.6T patent/LT3656758T/lt unknown
- 2013-02-08 WO PCT/US2013/025387 patent/WO2013119985A1/en not_active Ceased
- 2013-02-08 EP EP24161059.1A patent/EP4403552B1/en active Active
-
2016
- 2016-08-03 US US15/227,230 patent/US10030041B2/en active Active
-
2018
- 2018-06-26 US US16/018,401 patent/US10590157B2/en active Active
-
2019
- 2019-11-11 CY CY20191101180T patent/CY1122358T1/el unknown
-
2020
- 2020-02-05 US US16/783,025 patent/US10882881B2/en active Active
- 2020-12-04 US US17/112,060 patent/US11390640B2/en active Active
-
2022
- 2022-07-12 US US17/863,135 patent/US12024536B2/en active Active
-
2024
- 2024-05-17 US US18/667,496 patent/US12679860B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2812341T1 (sl) | C-terminalni inhibitorji HSP90 | |
| PL3434695T3 (pl) | Ulepszona immunoterapia | |
| IL238391A (en) | Rock inhibitors | |
| GB201009732D0 (en) | Direct cloning | |
| EP2857033A4 (en) | PEPTIDE WITH SKIN PERMEATION | |
| ZA201406225B (en) | Thiadiazolidinediones as gsk-3 inhibitors | |
| GB201009853D0 (en) | HSP90 inhibitors | |
| EP2885291A4 (en) | INHIBITORS OF VEGFR3 | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| EP2885292A4 (en) | VEGFR3 INHIBITORS | |
| GB2504497B (en) | Armour | |
| ZA201503275B (en) | Transporter | |
| ZA201503127B (en) | Peptides | |
| GB201200555D0 (en) | Peptide | |
| GB201204868D0 (en) | Peptides | |
| GB201213560D0 (en) | Armour | |
| GB201223114D0 (en) | Novel peptide | |
| EP2891663A4 (en) | PSF1-DERIVED PEPTIDE | |
| GB201220529D0 (en) | No details available | |
| GB201221414D0 (en) | Trans-locating peptide | |
| GB201200623D0 (en) | Peptide | |
| GB201200624D0 (en) | Peptide | |
| GB201220328D0 (en) | Peptides | |
| GB201211740D0 (en) | Peptides | |
| GB201207895D0 (en) | Peptides |